(Q34726613)

4 August 2017

Effect of the new antiepileptic drug retigabine in a rodent model of mania (English)

1 reference

4 August 2017

Ditte Dencker

1

1 reference

4 August 2017

Rebecca Dias

series ordinal

2

1 reference

4 August 2017

Mette Lund Pedersen

series ordinal

3

1 reference

4 August 2017

Henriette Husum

series ordinal

4

1 reference

4 August 2017

1 January 2008

1 reference

4 August 2017

1 reference

4 August 2017

12

1 reference

4 August 2017

1

1 reference

4 August 2017

49-53

1 reference

M-channels: neurological diseases, neuromodulation, and drug development.

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

KCNQ/M currents in sensory neurons: significance for pain therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Localization of KCNQ5 in the normal and epileptic human temporal neocortex and hippocampal formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Neuronal KCNQ potassium channels: physiology and role in disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

A potassium channel mutation in neonatal human epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Retigabine: chemical synthesis to clinical application.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

PP2A-Bgamma subunit and KCNQ2 K+ channels in bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Retigabine: in partial seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Establishment of a battery of simple models for facets of bipolar disorder: a practical approach to achieve increased validity, better screening and possible insights into endophenotypes of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Perspectives for the development of animal models of bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Hyperactivity induced by dexamphetamine/chlordiazepoxide mixtures in rats and its attenuation by lithium pretreatment: a role for dopamine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Combined Effects of Chlordiazepoxide and Dexamphetamine on Activity of Rats in an Unfamiliar Environment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Effect of the New Antiepileptic Drug Levetiracetam in an Animal Model of Mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Magnesium valproate attenuates hyperactivity induced by dexamphetamine-chlordiazepoxide mixture in rodents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Effect of lithium administration on rat brain 5-hydroxyindole levels in a possible animal model for mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Potassium channels as anti-epileptic drug targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Physiopathology of bipolar disorders: what have changed in the last 10 years?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Amphetamine: effects on catecholamine systems and behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

The KCNQ channel activator retigabine blocks haloperidol-induced c-Fos expression in the striatum of the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

An Exploratory Open Trial on Safety and Efficacy of the Anticonvulsant Retigabine in Acute Manic Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Modulation of calcium and potassium currents by lamotrigine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

4-aminopyridine and barium chloride attenuate the anti-epileptic effect of carbamazepine in hippocampal slices.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

Effects of valproate on early and late potassium currents of single neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2007.09.023

10.1016/J.YEBEH.2007.09.023

7 January 2021

Identifiers

DOI

1 reference

4 August 2017

1 reference